Previous month:
August 2011
Next month:
October 2011

Data Reveals Less Invasive FUE Hair Transplant Trend is Accelerating

Major Increase in Less Invasive Hair Transplants - FUE Doubles Since 2008 

PR Web Summary:  International Society of Hair Restoration Surgery Census finds dramatic growth in worldwide demand for hair restoration surgery which Dr. Alan Bauman attributes to the increased use of FUE hair transplants. Bauman expects the number of FUE hair transplants will surpass the traditional strip-harvest method in as little as three to five years.

Boca Raton, FL – In spite of the sluggish global economy, demand for hair restoration surgery is on the rise - increasing 15 percent in the US and 66 percent worldwide between 2004 and 2010, according to the International Society of Hair Restoration Surgery’s 2011 Practice Census. The key reason for this spike in procedures, according to ISHRS member Alan J. Bauman, M.D., is the demand for a less-invasive hair transplant procedure known as Follicular-Unit Extraction, or FUE.

“I remember vividly back in 2003 at the ISHRS Orlando Live Surgery Workshop where I demonstrated the first live FUE procedure performed at that conference, that many doctors were reluctant to adopt the challenging technique, preferring instead to persist with the traditional strip-harvest method,” said Dr. Bauman, a board-certified hair restoration surgeon and member of the ISHRS Media Relations Committee. “Only recently have more doctors rushed to offer FUE, and it’s plain to see how well patients are responding to it.”

FUE has proven to be a major advancement for the field of hair loss as it allows the surgeon to restore living and growing hair to balding patients without the traditional removal of a large strip of ‘donor’ skin from the back of the head. This traditional strip-harvest method requires the use of scalpel and stitches – and results in a tell-tale linear scar at the donor site. It’s easy to see why patients would prefer the less-invasive no-scalpel/no-stitch FUE over the traditional strip-harvest method. Now that FUE is gaining increased acceptance in the hair transplant community, and there is a growing track record of results worldwide, patient demand is soring – even in spite of the sluggish economy.

Key findings of the 2011 ISHRS Practice Census:

  • The total number of hair transplants performed worldwide in 2010 rose to 279,381 - an increase of 66 percent since 2004 and an 11 percent gain since 2008.
  • Less-invasive FUE no-scalpel/no-stitch harvesting techniques have increased exponentially in popularity while the total numbers of traditional “linear” or strip-harvest surgery have continued to drop.
  • In 2008, FUE procedures comprised just 11 percent of all hair transplants compared to the 22 percent share of the market they hold today—more than doubling the total amount of FUE procedures performed over the same time and tripling since 2004.
  • Strip-harvest surgeries dropped from 92 percent of all hair transplant procedures performed in 2004 to 77.5 percent of these procedures today.

Surgeons disagree whether strip-harvesting will ever be completely abandoned; but few will argue that the procedure is in decline. In fact, as mentioned in his recent lecture at the ISHRS Annual Scientific Meeting held in Anchorage Alaska September 14-18, Bauman presented statistical data that suggests that strip-harvest surgeries are already 'past their peak' and could be surpassed by minimally-invasive FUE procedures in as little as three to five years. New technology like NeoGraft, as well as futuristic technology like robotic transplants, could further accelerate this trend.

“At Bauman Medical Group, we’ve seen FUE cases jump from 10 percent in 2004/2006 to 50 percent in 2008 and now 90 percent in 2010 – literally ahead of the worldwide curve,” Bauman said. 


For the complete presentation and data from Dr. Alan Bauman's lecture at 2011 ISHRS Annual Scientific Meeting in Anchorage, Alaska on September 16th 2pm, visit

The ISHRS Census Survey data can be found at

For more information about FUE and NeoGraft FUE, visit Bauman Medical Group online.



Alan J. Bauman, M.D., founder of Bauman Medical Group in Boca Raton, Florida, is a internationally renowned hair transplant surgeon who has been featured extensively in the national and international print and television media, such as Newsweek, The New York Times, Cosmo, Vogue, Allure, Men's Health, Today Show, The Early Show, Good Morning America, Extra, Access Hollywood and Dateline NBC.

Dr. Bauman is recognized within the medical profession as top U.S. medical expert on the treatment of hair loss in men and women. A board-certified hair restoration surgeon, Dr. Bauman was the first to demonstrate ‘live’ the FUE method of hair transplantation at the 2003 International Society of Hair Restoration Surgery Orlando Live Surgery Workshop and the first to demonstrate the NeoGraft FUE device at the ISHRS Orlando Live Surgery Workshop in 2010. His practice is divided equally between male and female patients, and Dr. Bauman provides state-of-the-art diagnostic procedures and a multi-therapy approach to the medically treatable condition of hair loss. Dr. Bauman is a member and often a featured speaker at the American Academy of Anti-Aging Medicine and the International Society of Hair Restoration Surgery annual scientific meetings. 

Editors Note: Dr. Bauman is available for expert medical media commentary. To arrange for an interview at his 5,000 square foot state-of-the-art medical clinic, or plan a phone, or live in-studio interview, call media relations contact: Janet Shoup at 828-707-8971;


Kythera Biopharmaceuticals Announces $37.4M Financing for ATX-101 Synthetic Fat Melting Injection

Return to Current Article

Kythera Newsroom

LOS ANGELES, Sept. 19 (Business Wire) – KYTHERA Biopharmaceuticals, Inc. (“KYTHERA”), a privately-held biotechnology company focused on the development and commercialization of products in aesthetic medicine, today announced the closing of a $37.4M Series D financing. The round featured significant new investments as well as participation from all existing institutional investors. Proceeds from this financing are slated to be used for conducting US Phase III trials for KYTHERA’s lead product, ATX-101, a first-in-class, injectable drug that is under investigation for the reduction of submental (‘under the chin’) fat.

It would appear that ATX-101 holds some promise for those looking for an injection that reduces submental (chin/neck) fat. --Dr. Alan Bauman

Use of Platelet Rich Plasma Gel on Wound Healing: A Systematic Review and Meta-AnalysisePlasty: Vol. 11

There were 21 publications that were RCT or comparative non-RCT designs in this systematic review. Given the physiological and healing differences between acute and chronic wounds, the citations were divided by study design and by type of wound prior to review and meta-analysis. The primary outcome assessed in this systematic review was complete healing. In both chronic and acute wound studies, complete wound closure was more likely in wounds treated with PRP therapy. Similar partial healing and wound area/volume reduction outcomes were noted more frequently with the PRP-treated wounds likely because the therapy is discontinued once the wound begins healing. This meta-analysis and other systematic reviews show PRP has sufficient efficacy to stimulate healing in stalled wounds. One systematic review concluded that the percentage of total healing in PRP-treated skin ulcers consistently increased compared to controls.7 The meta-analysis of chronic wound studies confirmed the use of PRP treatment favored complete healing compared to control care. Other systematic reviews on PRP therapy reached the same conclusions.7-9 One systematic review went so far as to conclude that based on the meta-analysis and scientific evidence regarding consistent favorable outcomes, PRP is a treatment of choice for the topical care of wounds.9


This is an impressive collection of PRP literature and certainly supports the use of PRP as a wound healing treatment and confirms what we are seeing when we use PRP for wound healing in hair transplants. --Dr. Alan J. Bauman.

Cytomedix Launches PRP Hair Restoration Wound Care Program at the International Society of Hair Restoration Surgeons Annual Meeting - MarketWatch

GAITHERSBURG, Md., Sep 15, 2011 (GlobeNewswire via COMTEX) -- Cytomedix, Inc. /quotes/zigman/3795200 CMXI +7.44% (the "Company"), a leading developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis, today announced the launch of the Company's Hair Restoration Wound Care Program at the 19th Annual Scientific Meeting of the International Society of Hair Restoration Surgeons being held from September 14-18 in Anchorage, Alaska.

Cytomedix is showcasing the AutoloGel(TM) System at their exhibit where hair restoration surgeons can learn more about the benefits of AutoloGel PRP Gel to enhance outcomes in hair transplant surgery. In conjunction with this outreach, the Company introduced its web-based marketing initiative with the launch of , a website designed to provide hair restoration specialists with the tools to integrate PRP Gel into their post-operative wound care protocols, the rationale for use and the science behind PRP for follicular unit transplant, as well as to generate new patient referrals. The site also provides a fast-growing list of surgeons offering AutoloGel PRP in their practice.

Alan J. Bauman, M.D., Board Certified hair restoration surgeon, Boca Raton, Florida, stated, "The use of AutoloGel PRP applied to hair transplant wounds has had a positive impact on the rate and quality of post-operative care. Both our experienced team and our patients are delighted with the simplicity and speed of the PRP gel technique and the visual improvement in wound recovery one day post-surgery."

We've found that the FDA-approved PRP wound healing system, Autologel, has been working very well to accelerate the wound healing in our NeoGraft FUE hair transplant patients. Decreased discomfort, inflammation and faster cosmetic recovery are some of the added benefits of PRP. --Dr. Alan Bauman

Yale Scientists Find Stem Cells That Tell Hair It’s Time to Grow

Published: September 1, 2011

New Haven, Conn. — Yale researchers have discovered the source of signals that trigger hair growth, an insight that may lead to new treatments for baldness.

The researchers identified stem cells within the skin's fatty layer and showed that molecular signals from these cells were necessary to spur hair growth in mice, according to research published in the Sept. 2 issue of the journal Cell.

It sometimes seems like a change in the wind causes hair to grow in mice... But seriously, can adipose derived stem cells hold an important key to treating hair loss? --Dr. Alan J. Bauman

RepliCel(TM) hair follicle replication first-in-man trial injects final patient

This press release was made public this morning...

RepliCel Injects Final Patient with Hair Follicle Cells in its First-In-Man Clinical Trial TS001-2009
VANCOUVER, BC – September 7, 2011 - RepliCel Life Sciences Inc. (the “Company” or “RepliCel”) (OTCBB: REPCF) is pleased to report that the final study participant has received injections of hair follicle cells prepared using RepliCel™ technology. This milestone marks the end of the treatment phase of the TS001-2009 clinical trial in which a total of nineteen participants received injections.  To date, no serious adverse events have been reported post-injection.  Please note that recruitment of subjects was closed at nineteen (rather than the planned twenty) to allow for timely processing of interim analysis data from the six-month follow-up time point.  This interim analysis is scheduled to take place in Q1, 2012.
In the next stage of the TS001-2009 trial, the post-injection follow-up period, subjects return to the study centre to have their health closely monitored to ensure that there have been no adverse effects associated with receiving the injections and to determine the hair growth stimulating efficacy of the hair follicle cell injections.
Once the final patient has completed their six-month follow-up visit, an interim analysis of all collected data will be performed to assess the primary outcome measure of the TS001-2009 study.  The analysis will involve assessment of the local (at treatment sites) safety profile of autologous hair follicle cells compared to placebo as defined by AEs with respect to their causality, incidence, severity and seriousness.  Secondary outcome measures of systemic (overall) safety (through review of adverse events in a similar fashion as described above) and efficacy (hair growth at treatment sites) will also be performed at this time.  Subjects will participate in the post-injection follow-up period of the study until August 2013 and final analysis of safety data should be available in late 2013.
TS001-2009 Clinical Trial Overview
The TS001-2009 clinical trial is designed to test the safety and efficacy of the RepliCel™ technology in men and women with androgenetic alopecia.  This single-centre study enrolled subjects with alopecia categorized as either vertex pattern type II or type III on the Ludwig Scale (female) or as type III vertex to type VI on the Norwood Scale (male).  At the beginning of the trial, subjects provided blood samples to confirm their health status and biopsies were taken from their scalps from which hair follicle cells were processed using RepliCel™ technology.  Once cell processing was complete, subjects returned to the study centre to have baseline measurements of their overall health and the health of their scalps.  They then received injections of their own replicated cells (autologous cells) in medium (verum) and medium alone (placebo) into two pre-selected treatment areas in their scalps.
In the post-injection follow-up period, subjects return to the clinic for 10 visits over the next 24 months. At these visits, subjects have their overall health assessed, as well as subjective and objective assessments of the areas that were injected either with verum or placebo. Digital images will be taken of the scalp to assess any changes to the scalp post-injection and the differences in health and hair growth between the two treatment areas. Furthermore, at 6, 12, and 24 months post-injection, four subjects at each time point will provide biopsies of the injection sites for histopathological analysis. The total duration of subject participation in the study is approximately 27 months.
Tammey George, Director of Communications
Telephone: 604-248-8696

It will be interesting to see the interim analysis next year! --Dr. Alan J. Bauman

Latanoprost prostaglandin analogue for hair loss in men

Latanoprost is a prostaglandin analogue used to treat glaucoma. It can cause adverse effects, such as iridial and periocular hyperpigmentation, and eyelash changes including pigmentation and increased thickness, length, and number. Latanoprost has been used to treat eyelash alopecia, but knowledge on its effects on human scalp hair growth is not available.


Latanoprost is a prostaglandin analogue similar to bimatoprost. This category of medication is gaining some interesting momentum as a treatment option for those with early male pattern hair loss. Allergan is already in clinical trials to seek FDA-approval for hair growth on the scalp for their prostaglanding analogue, bimatoprost (Latisse). --Dr. Alan Bauman


J Am Acad Dermatol. 2011 Aug 27. [Epub ahead of print]
A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia.
Blume-Peytavi U, Lönnfors S, Hillmann K, Bartels NG.
Department of Dermatology and Allergy, Clinical Research Center for Hair and Skin Science, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Latanoprost is a prostaglandin analogue used to treat glaucoma. It can cause adverse effects, such as iridial and periocular hyperpigmentation, and eyelash changes including pigmentation and increased thickness, length, and number. Latanoprost has been used to treat eyelash alopecia, but knowledge on its effects on human scalp hair growth is not available.
The primary objectives were to assess the efficacy of latanoprost on hair growth and pigmentation. The secondary objectives were to assess the effect on scalp pigmentation; investigate the treatment duration needed to affect hair growth, hair pigmentation, and scalp pigmentation; and assess safety of latanoprost.
Sixteen men with mild androgenetic alopecia (Hamilton II-III) were included. Latanoprost 0.1% and placebo were applied daily for 24 weeks on two minizones on the scalp. Measurements on hair growth, density, diameter, pigmentation, and anagen/telogen ratio were performed throughout the study.
At 24 weeks, an increased hair density on the latanoprost-treated site was observed compared with baseline (n = 16, P < .001) and placebo-treated site (P = .0004).
Only young men with mild androgenetic alopecia were included. The results may not be applicable to other patient groups. Choice of investigational site may have affected the results.
Latanoprost significantly increased hair density (terminal and vellus hairs) at 24 weeks compared with baseline and the placebo-treated area. Latanoprost could be useful in stimulating hair follicle activity and treating hair loss.
Copyright © 2011 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.
[PubMed - as supplied by publisher]